Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
To evaluate the superiority of brexpiprazole 1 mg or 2 mg over placebo after a 10-week
treatment regimen for agitation associated with dementia of the Alzheimer's type in patients
who require medication, and to investigate the safety of brexpiprazole and identify the
optimum dose.